LTGO on Nasdaq

Latigo Biotherapeutics, Inc.

American pharmaceutical preparations company based in Thousand Oaks. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerLTGO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersThousand Oaks, California1
  • Incorporated inDE2
  • Business address1300 Rancho Conejo Blvd., Suite 305, Thousand Oaks, Ca2
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Fiscal year2025
Dividend per share$0.003

Compare Latigo Biotherapeutics, Inc. with another company

Leadership

Who has led Latigo Biotherapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nima Farzan2026–now

President

  1. Nima Farzan2026–now

Chief financial officer

  1. Neha Krishnamohan2026–now
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerTim Lugo named Feb 13, 202511
  • DirectorDeborah Palestrant named Feb 13, 202511
  • DirectorJim Tananbaum named Feb 13, 202511
  • DirectorNancy Stagliano named Feb 13, 202511

Timeline

  1. Aug 6, 2026New chief executive Nima Farzan becomes CEO4

Filings

40 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 20 insider forms, 4 large holders, 1 private raises, 12 other. The latest 20:

  1. Sep 3, 202610-Q EDGAR
  2. Sep 3, 20268-K EDGAR
  3. Aug 18, 2026SCHEDULE 13G EDGAR
  4. Aug 17, 2026SCHEDULE 13G EDGAR
  5. Aug 17, 2026SCHEDULE 13D EDGAR
  6. Aug 13, 2026SCHEDULE 13G EDGAR
  7. Aug 12, 20264 EDGAR
  8. Aug 12, 20264 EDGAR
  9. Aug 12, 20263 EDGAR
  10. Aug 11, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Aug 10, 20264 EDGAR
  12. Aug 10, 20264 EDGAR
  13. Aug 10, 2026S-8 EDGAR
  14. Aug 10, 20268-K EDGAR
  15. Aug 10, 20264 EDGAR
  16. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Aug 7, 2026424B4 EDGAR
  18. Aug 6, 2026EFFECT EDGAR
  19. Aug 6, 20263 EDGAR
  20. Aug 6, 20263 EDGAR

The 40 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 10, 2026Tananbaum James B.DirectorBuy140,000$18.00$2.5MForm 4
Aug 10, 2026Foresite Capital Fund VI LP10% ownerBuy140,000$18.00$2.5MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 28, 2025Raised $50 million in a private offering of equity Form D: $150 million offered in all Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15